Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
30.96
+0.17
+(0.55%)
As of 8:44:38 AM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO | -- | -- | 1965 |
| Mr. Terrance P. Coyne | Executive VP & CFO | 4.29M | -- | -- |
| Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer | 4.29M | -- | 1960 |
| Mr. Christopher Hite | Vice Chairman & Executive VP | 4.29M | -- | 1968 |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments | 4.29M | -- | 1977 |
| Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel | -- | -- | -- |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments | -- | -- | -- |
| Ms. Kristin Stafford | Senior VP & Chief Accounting Officer | -- | -- | 1983 |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer | -- | -- | -- |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer | 3.2M | -- | 1971 |
Royalty Pharma plc
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Corporate Governance
Royalty Pharma plc’s ISS Governance QualityScore as of March 1, 2025 is 4. The pillar scores are Audit: 4; Board: 4; Shareholder Rights: 6; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Royalty Pharma plc Earnings Date
Recent Events
February 21, 2025 at 12:00 AM UTC
Ex-Dividend Date
Related Tickers
HQ1.MU Oruka Therapeutics Inc. R
9.60
0.00%
5KW.F SkinBioTherapeutics plc
0.2160
-2.70%
5CV.MU CureVac NV
2.8900
+0.35%
AM6.F Amicus Therapeutics, Inc.
8.40
-1.18%
ICY.SG Incyte Corp
64.34
+0.06%
600161.SS TIANTAN BIO
19.88
+0.05%
GON.DU Geron Corp
1.5660
+0.51%
1S9.SG Seres Therapeutics Inc
0.6902
+1.77%
ISI.F Ionis Pharmaceuticals, Inc.
31.00
-0.06%
2H51.DU Ocugen Inc
0.5385
+3.86%